Company Strengthens Supply Chain Operations as it Prepares for
Potential Approval and Launch of KTE-C19 for Aggressive non-Hodgkin
Lymphoma by the U.S. Food and Drug Administration in 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)--
Kite Pharma, Inc. (Nasdaq: KITE)
today announced the appointment of Jian Irish, Ph.D. as the company's
Senior Vice President of Supply Chain. The appointment of Dr. Irish, who
will be responsible for establishing and securing a reliable supply
chain, including sourcing, logistics, inventory management, procurement,
supply and operations planning process, further increases the depth of
an industry-leading cell therapy Supply Chain organization.
"Jian brings a wealth of supply chain and product development experience
to Kite, as well as extensive international business acumen," said Tim
Moore, Executive Vice President, Technical Operations of Kite. "Her
willingness to embrace new opportunities to innovate, coupled with her
ability to partner and cultivate talent, makes Jian a great addition to
the Technical Operations senior leadership team."
Dr. Irish will work closely with both the commercial and technical
operations organization to create operational strategies for supply
chain design, product life cycle management, launch and
commercialization as the company prepares for the potential approval of
Kite's lead product candidate, KTE-C19, by the U.S. Food and Drug
"Coming from a family of medical doctors, I learned from a very young
age to appreciate the power that medicine has to change lives," said Dr.
Irish. "I am excited to be a part of Kite, a company that is
increasingly recognized for its leadership in CAR-T therapy as well as
its drive to find a cure for cancer. I look forward to partnering with a
stellar team of experienced professionals who have a common commitment
to excellence at every level."
Dr. Irish established her career in the biopharmaceutical industry
through various global leadership roles. She joins Kite from Sanofi,
where she most recently served as the Vice President of Biologics
Strategic Supply, Sourcing and Partnerships. She also served as Vice
President of Biologics Product Development Technology Transfer at
Sanofi. In these roles, Dr. Irish oversaw the strategy and execution of
the Biologics supply chain and technical transfer processes to scale up
Sanofi Biological operations. Prior to Sanofi, Dr. Irish was the
Executive Director, General Manager of Japan Asia Pacific Supply Chain
at Amgen as well as the Executive Director, Global Head of Contract
Manufacturing where Dr. Irish made a critical impact in the
commercialization of Vectibix®, Xgeva®, and Enbrel®.
Dr. Irish holds a Bachelor of Science in Chemical Engineering from East
China University of Science and Technology in Shanghai, China, a Master
of Science and Ph.D. in Pharmaceutical Sciences from Chiba University in
Chiba, Japan, and a Master of Business Administration from the Anderson
School of Management at University of California, Los Angeles.
Kite Pharma's lead product candidate, KTE-C19, is an investigational
therapy in which a patient's T cells are engineered to express a
chimeric antigen receptor (CAR) to target the antigen CD19, a protein
expressed on the cell surface of B-cell lymphomas and leukemias, and
redirect the T cells to kill cancer cells. KTE-C19 has been granted
Breakthrough Therapy Designation status for diffuse large B-cell
lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary
mediastinal B-cell lymphoma (PMBCL) by the U.S. Food and Drug
Administration (FDA) and Priority Medicines (PRIME) regulatory support
for DLBCL in the EU.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged
in the development of novel cancer immunotherapy products, with a
primary focus on engineered autologous cell therapy (eACT™) designed to
restore the immune system's ability to recognize and eradicate tumors.
Kite is based in Santa Monica, CA. For more information on Kite Pharma,
please visit www.kitepharma.com.
Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the ability and
timing of filing a biologics license application with the FDA, obtaining
regulatory approval based on the studies of KTE-C19, commercially
launching KTE-C19, and the ability to establish and secure a reliable
supply chain for KTE-C19. Various factors may cause differences between
Kite's expectations and actual results as discussed in greater detail in
Kite's filings with the Securities and Exchange Commission, including
without limitation in its Form 10-Q for the quarter ended September 30,
2016. Any forward-looking statements that are made in this press release
speak only as of the date of this press release. Kite assumes no
obligation to update the forward-looking statements whether as a result
of new information, future events or otherwise, after the date of this
View source version on businesswire.com: http://www.businesswire.com/news/home/20161201005388/en/
SVP, Corporate Communications &
VP, Investor Relations
Source: Kite Pharma, Inc.
News Provided by Acquire Media